161 related articles for article (PubMed ID: 16908138)
1. Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds.
Beaulieu PL; Gillard J; Bykowski D; Brochu C; Dansereau N; Duceppe JS; Haché B; Jakalian A; Lagacé L; LaPlante S; McKercher G; Moreau E; Perreault S; Stammers T; Thauvette L; Warrington J; Kukolj G
Bioorg Med Chem Lett; 2006 Oct; 16(19):4987-93. PubMed ID: 16908138
[TBL] [Abstract][Full Text] [Related]
2. Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells.
Beaulieu PL; Bousquet Y; Gauthier J; Gillard J; Marquis M; McKercher G; Pellerin C; Valois S; Kukolj G
J Med Chem; 2004 Dec; 47(27):6884-92. PubMed ID: 15615537
[TBL] [Abstract][Full Text] [Related]
3. From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons.
Beaulieu PL; Gillard J; Jolicoeur E; Duan J; Garneau M; Kukolj G; Poupart MA
Bioorg Med Chem Lett; 2011 Jun; 21(12):3658-63. PubMed ID: 21550240
[TBL] [Abstract][Full Text] [Related]
4. Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.
Harper S; Pacini B; Avolio S; Di Filippo M; Migliaccio G; Laufer R; De Francesco R; Rowley M; Narjes F
J Med Chem; 2005 Mar; 48(5):1314-7. PubMed ID: 15743173
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
[TBL] [Abstract][Full Text] [Related]
6. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.
Beaulieu PL; Bös M; Bousquet Y; Fazal G; Gauthier J; Gillard J; Goulet S; LaPlante S; Poupart MA; Lefebvre S; McKercher G; Pellerin C; Austel V; Kukolj G
Bioorg Med Chem Lett; 2004 Jan; 14(1):119-24. PubMed ID: 14684311
[TBL] [Abstract][Full Text] [Related]
7. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
[TBL] [Abstract][Full Text] [Related]
8. Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole.
Ishida T; Suzuki T; Hirashima S; Mizutani K; Yoshida A; Ando I; Ikeda S; Adachi T; Hashimoto H
Bioorg Med Chem Lett; 2006 Apr; 16(7):1859-63. PubMed ID: 16455252
[TBL] [Abstract][Full Text] [Related]
9. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
[TBL] [Abstract][Full Text] [Related]
10. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109.
Hirashima S; Suzuki T; Ishida T; Noji S; Yata S; Ando I; Komatsu M; Ikeda S; Hashimoto H
J Med Chem; 2006 Jul; 49(15):4721-36. PubMed ID: 16854079
[TBL] [Abstract][Full Text] [Related]
11. Characterization of aurintricarboxylic acid as a potent hepatitis C virus replicase inhibitor.
Chen Y; Bopda-Waffo A; Basu A; Krishnan R; Silberstein E; Taylor DR; Talele TT; Arora P; Kaushik-Basu N
Antivir Chem Chemother; 2009 Sep; 20(1):19-36. PubMed ID: 19794229
[TBL] [Abstract][Full Text] [Related]
12. The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity.
Laporte MG; Jackson RW; Draper TL; Gaboury JA; Galie K; Herbertz T; Hussey AR; Rippin SR; Benetatos CA; Chunduru SK; Christensen JS; Coburn GA; Rizzo CJ; Rhodes G; O'Connell J; Howe AY; Mansour TS; Collett MS; Pevear DC; Young DC; Gao T; Tyrrell DL; Kneteman NM; Burns CJ; Condon SM
ChemMedChem; 2008 Oct; 3(10):1508-15. PubMed ID: 18729128
[No Abstract] [Full Text] [Related]
13. Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase.
Harper S; Avolio S; Pacini B; Di Filippo M; Altamura S; Tomei L; Paonessa G; Di Marco S; Carfi A; Giuliano C; Padron J; Bonelli F; Migliaccio G; De Francesco R; Laufer R; Rowley M; Narjes F
J Med Chem; 2005 Jul; 48(14):4547-57. PubMed ID: 15999993
[TBL] [Abstract][Full Text] [Related]
14. Indole 5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase with nanomolar potency in cell-based subgenomic replicons (part 2): central amino acid linker and right-hand-side SAR studies.
Beaulieu PL; Chabot C; Duan J; Garneau M; Gillard J; Jolicoeur E; Poirier M; Poupart MA; Stammers TA; Kukolj G; Tsantrizos YS
Bioorg Med Chem Lett; 2011 Jun; 21(12):3664-70. PubMed ID: 21592789
[TBL] [Abstract][Full Text] [Related]
15. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency.
Beaulieu PL; Bös M; Bousquet Y; DeRoy P; Fazal G; Gauthier J; Gillard J; Goulet S; McKercher G; Poupart MA; Valois S; Kukolj G
Bioorg Med Chem Lett; 2004 Feb; 14(4):967-71. PubMed ID: 15013003
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: potent allosteric inhibitors of the hepatitis C virus NS5B polymerase.
Ding M; He F; Hudyma TW; Zheng X; Poss MA; Kadow JF; Beno BR; Rigat KL; Wang YK; Fridell RA; Lemm JA; Qiu D; Liu M; Voss S; Pelosi LA; Roberts SB; Gao M; Knipe J; Gentles RG
Bioorg Med Chem Lett; 2012 Apr; 22(8):2866-71. PubMed ID: 22424979
[TBL] [Abstract][Full Text] [Related]
17. The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture.
Klumpp K; Lévêque V; Le Pogam S; Ma H; Jiang WR; Kang H; Granycome C; Singer M; Laxton C; Hang JQ; Sarma K; Smith DB; Heindl D; Hobbs CJ; Merrett JH; Symons J; Cammack N; Martin JA; Devos R; Nájera I
J Biol Chem; 2006 Feb; 281(7):3793-9. PubMed ID: 16316989
[TBL] [Abstract][Full Text] [Related]
18. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
[TBL] [Abstract][Full Text] [Related]
19. Discovery of HCV NS5B thumb site I inhibitors: core-refining from benzimidazole to indole scaffold.
Zhao F; Liu N; Zhan P; Jiang X; Liu X
Eur J Med Chem; 2015 Apr; 94():218-28. PubMed ID: 25768704
[TBL] [Abstract][Full Text] [Related]
20. Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate.
McKercher G; Beaulieu PL; Lamarre D; LaPlante S; Lefebvre S; Pellerin C; Thauvette L; Kukolj G
Nucleic Acids Res; 2004; 32(2):422-31. PubMed ID: 14739234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
